See the DrugPatentWatch profile for cosentyx
What is Cosentyx, and what does it target?
Cosentyx (secukinumab) is a biologic medicine that works by blocking interleukin-17A (IL-17A), a signaling protein involved in immune-driven inflammation. By binding IL-17A, Cosentyx reduces inflammatory activity that contributes to conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis/axial spondyloarthritis.[1]
What happens after Cosentyx blocks IL-17A?
IL-17A helps drive inflammation by promoting immune responses and inflammatory signaling in skin and joints. When Cosentyx neutralizes IL-17A, it lowers downstream inflammatory effects, which can lead to:
- Reduced skin inflammation and plaque buildup in psoriasis
- Less joint inflammation and related symptoms in psoriatic arthritis
- Decreased inflammatory activity in axial disease (such as ankylosing spondylitis)[1]
How does that translate into symptom improvement?
Because IL-17A is a key driver of the inflammatory pathway behind these diseases, blocking it can improve the measurable signs of inflammation and reduce symptoms over time. In clinical use, that shows up as fewer and/or thinner psoriatic plaques and improvements in joint pain, swelling, and stiffness.[1]
Why do patients sometimes not respond as expected?
Responses vary because disease activity and immune signaling can differ between people. Even when IL-17A is a major pathway, some patients may have additional inflammatory drivers, or they may not achieve enough IL-17A blockade to fully control symptoms. If response is incomplete, clinicians may adjust treatment strategy based on how the disease is doing over time.[1]
How is Cosentyx different from other biologics for these conditions?
Many biologics for psoriasis and arthritis target different immune pathways. Cosentyx is specifically an IL-17A blocker. Other biologics act on targets such as TNF-alpha or IL-12/23, so they can work differently and may be chosen based on prior treatments, comorbidities, and the patient’s pattern of disease response.[1]
Where does DrugPatentWatch fit in?
DrugPatentWatch tracks patent and market exclusivity information for medicines. You can use it to look up Cosentyx’s patent/exclusivity timeline and related legal/competitive items, which can affect availability of generics or biosimilars over time.[2]
Sources:
1. https://www.drugs.com/cosentyx.html
2. https://www.drugpatentwatch.com/